COSA 2020: Omitting Ranitidine From Paclitaxel-Containing Protocols Does Not Raise the Incidence or Severity of Hypersensitivity Reactions
The finding needs to be confirmed in a larger retrospective study.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.